June 18, 2011 -- GSK will pay $39 million to Neptunus Interlong for the 51% of their China flu vaccine JV that it does not already own; Zhejiang Conba Pharma announced an oncology JV with American Kite Pharma; US-based LabCorp will acquire Clearstone Central Laboratories, which owns facilities in Beijing and Singapore; PKU Southwest Synthetic Pharma will issue 9.4 million shares to bring a distribution subsidiary entirely in-house; Unigene Laboratories, a US peptide company, closed out an eleven-year-old China JV; ClinTec International, a clinical stage CRO based in Scotland, opened four fully registered offices in China, Singapore and Thailand; Shandong Luoxin Pharmacy will develop cefazedone sodium, a narrow-spectrum antibiotic; Nycomed will market a Roche osteoporosis treatment, Bonviva, in China; and Rhei Pharma said its application for China marketing of MuGard™, a treatment for oral mucositis, was accepted by the SFDA. More details….
Stock Symbols: (NYSE: GSK) (HKEX: 8329) (SHA: 600572) (NYSE: LH) (SHE: 000788) (OTCBB: UGNE) (HKEX: 8058) (VS: ROG)
